Gene tests for aggressive breast cancer set to enter market

Monogram Biosciences announced Tuesday that its HERmark breast cancer assay, which is designed to detect an aggressive form of the disease by measuring protein levels of the HER2 gene, will be launched on July 15. Invitrogen Corp. has obtained FDA approval for SPOT-Light, a test that can count copies of the HER2 gene to identify which breast cancer patients are likely to respond to Genentech's Herceptin.

View Full Article in:

Wall Street Journal (tiered subscription model), The · American City Business Journals · Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA